Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of BMS-986533 in Healthy Participants
NCT07629999Phase 1Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BMS-986533 (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Number of participants with Adverse Events, Number of participants with Serious Adverse Events and 5 more. Started Jul 2026; status: recruiting.
02
Drugs
BMS-986533
Beyond the preview
Go deeper on NCT07629999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07629999.